Bone marrow from a young boy diagnosed with Diamond-Blackfan anemia (DBA) shows a reduced number of erythroid precursor cells. In this case, an unusual gene mutation in the hormone EPO was identified and found to cause the anemia. Photo courtesy of Ekrem Unal.
Startup Magenta Therapeutics licences technologies from Harvard, MGH, and Boston Children's that could transform treatment of blood diseases and immune disorders
Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases and immune disorders Read more about HSCI research inspires startup